Harbour BioMed and ProBioGen agree on a GlymaxX® License to Fast-Track Cell Line Development Projects
Berlin, Germany and Shanghai, China, February, 2nd, 2021: ProBioGen AG and Harbour BioMed today jointly announced their agreement on a cell line development project and..
ProBioGen licenses GlymaxX® Technology to AbbVie
Berlin, Germany, January 21st, 2021: ProBioGen AG has signed a commercial license agreement with AbbVie for applying ProBioGen’s proprietary GlymaxX® technology to boost the..
ProBioGen Successfully Completes CMC Development Milestones for Marea’s Promising Acromegaly Therapeutic
Mar 6, 2025
ProBioGen Launches New Website to Enhance User Experience and Streamline Access to Expanded Portfolio
Feb 4, 2025
Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Development
Nov 5, 2024
ModeX Therapeutics Leverages ProBioGen's Expertise for Accelerated COVID-19 Antibody Development
May 29, 2024
ProBioGen and DIOSynVax Partner to Manufacture Groundbreaking Multivalent Vaccine for Hemorrhagic Fever
Mar 27, 2024
ProBioGen Partners with MAPP BIOPHARMACEUTICAL, INC. for Groundbreaking Development of Afucosylated Antibody Against Marburg Virus Disease Using GlymaxX Technology
Mar 13, 2024
GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development
Sep 26, 2023
